Cellectar Biosciences Statistics
Total Valuation
CLRB has a market cap or net worth of $14.40 million. The enterprise value is -$8.40 million.
Important Dates
The next estimated earnings date is Tuesday, May 13, 2025, before market open.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CLRB has 46.08 million shares outstanding. The number of shares has increased by 203.92% in one year.
| Current Share Class | 46.08M |
| Shares Outstanding | 46.08M |
| Shares Change (YoY) | +203.92% |
| Shares Change (QoQ) | +5.39% |
| Owned by Insiders (%) | 1.64% |
| Owned by Institutions (%) | 13.02% |
| Float | 45.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.05 |
| P/TBV Ratio | 1.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.58, with a Debt / Equity ratio of 0.03.
| Current Ratio | 2.58 |
| Quick Ratio | 2.48 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -4,693.38% and return on invested capital (ROIC) is -2,196.39%.
| Return on Equity (ROE) | -4,693.38% |
| Return on Assets (ROA) | -172.36% |
| Return on Invested Capital (ROIC) | -2,196.39% |
| Return on Capital Employed (ROCE) | -321.87% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.05M |
| Employee Count | 11 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CLRB has paid $66,000 in taxes.
| Income Tax | 66,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.34% in the last 52 weeks. The beta is 0.67, so CLRB's price volatility has been lower than the market average.
| Beta (5Y) | 0.67 |
| 52-Week Price Change | -90.34% |
| 50-Day Moving Average | 0.31 |
| 200-Day Moving Average | 1.26 |
| Relative Strength Index (RSI) | 53.20 |
| Average Volume (20 Days) | 622,393 |
Short Selling Information
The latest short interest is 2.22 million, so 4.83% of the outstanding shares have been sold short.
| Short Interest | 2.22M |
| Short Previous Month | 2.92M |
| Short % of Shares Out | 4.83% |
| Short % of Float | 4.91% |
| Short Ratio (days to cover) | 1.54 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -51.78M |
| Pretax Income | -51.04M |
| Net Income | -44.58M |
| EBITDA | -51.49M |
| EBIT | -51.78M |
| Earnings Per Share (EPS) | -$1.40 |
Full Income StatementBalance Sheet
The company has $23.29 million in cash and $494,003 in debt, giving a net cash position of $22.79 million or $0.49 per share.
| Cash & Cash Equivalents | 23.29M |
| Total Debt | 494,003 |
| Net Cash | 22.79M |
| Net Cash Per Share | $0.49 |
| Equity (Book Value) | 15.68M |
| Book Value Per Share | 0.30 |
| Working Capital | 14.86M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$47.58 million and capital expenditures -$104,195, giving a free cash flow of -$47.69 million.
| Operating Cash Flow | -47.58M |
| Capital Expenditures | -104,195 |
| Free Cash Flow | -47.69M |
| FCF Per Share | -$1.03 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |